Enliven Therapeutics, Inc. 4

Chief Medical Officer Helen Louise Collins of Enliven Therapeutics, Inc. exercised 5,000 stock options at $2.48 and sold 5,000 common shares around the low-to-mid $50s on July 17, 2026, leaving her with 25,000 directly owned shares.

On July 17, 2026, Enliven Therapeutics, Inc. Chief Medical Officer Helen Louise Collins exercised a stock option to acquire 5,000 shares of common stock at an exercise price of $2.48 per share and subsequently sold an aggregate 5,000 shares in a series of market transactions at weighted-average prices between approximately $50.05 and $53.92 per share, all pursuant to a pre-established Rule 10b5-1 trading plan. The option exercise itself was recorded as an acquisition, taking her directly held common stock holdings to 30,000 shares before the sales; the ensuing five sale transactions reduced her direct ownership to 25,000 shares. Based on the reported sale prices, the total value of the exercised-and-sold shares was roughly $259,000, and her remaining 25,000 directly held shares are worth an estimated $1.25–$1.35 million using the low-to-mid $50s price context disclosed in the filing. The filing also notes that certain securities held by the reporting person are RSUs representing contingent rights to receive common stock, and that all shares subject to the reported option were fully vested and exercisable at the time of the transaction.

Filing Facts

CIK

1672619

Ticker

ELVN

Form

4

Source Type

fda

Accession

0001701247-26-000011

Alert Tier

6